GET DAILY SIGNALSNkarta (NKTX) Analyst Target at $11 Points to +700% Upside Potential
Key Takeaways
- The central stock price target used here is $11, the arithmetic mean of five current, individually verified analyst price targets, rounded from roughly $11.20.
- The latest verified close for Nkarta, Inc. (NKTX) was about $1.35, so reaching $11 would require a very large move of roughly 700%.
- Individual analyst targets range from about $9 to $14, with ratings concentrated in Buy and Strong Buy territory but with several firms trimming their figures in recent months.
- The bullish case rests on Nkarta's off-the-shelf natural killer (NK) cell therapy pipeline, led by NKX019 in autoimmune disease, and a cash runway reported into 2029.
- The biggest risks are clinical-stage binary outcomes, continued cash burn, heavy share-price decline, and the fact that even the lowest target sits far above where the stock trades.
- For more on the company's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages for timely updates.
Analyst Price Targets and Consensus View
Nkarta, Inc. (NKTX) is a clinical-stage biopharmaceutical company developing engineered, off-the-shelf natural killer (NK) cell therapies for cancer and autoimmune diseases. Its lead candidate, NKX019, is a CAR-NK therapy targeting the CD19 antigen being studied across autoimmune conditions such as lupus nephritis, systemic sclerosis, and ANCA-associated vasculitis.
The $11 central target is the arithmetic mean of five current analyst price targets, rounded from about $11.20. The attributable range spans roughly $9 to $14. Recent figures include H.C. Wainwright at $14 (trimmed from $16), Mizuho at $12 (trimmed from $14), Needham at $11, Stifel at $10 (trimmed from $11), and Evercore ISI at $9 (cut sharply from $25). TD Cowen initiated coverage with a Buy rating in mid-2026 without a published target. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The pattern is notable: ratings have stayed bullish, but several firms have lowered their targets. This suggests analysts are recalibrating valuation assumptions rather than abandoning the long-term thesis. No material downgrades have been reported among these firms, and the overall stance remains a Strong Buy or Buy consensus, though the wide spread between the lowest and highest targets reflects genuine uncertainty about clinical and financing risk.
Current Market Position and Path Toward the Target
As of the most recent verified close, NKTX traded near $1.35, down sharply in a single session. Reaching the $11 central target would require a rise of roughly 700%, which is a very large move by any standard. The stock sits well below its 52-week range of about $1.13 to $3.72, and its market capitalization is roughly $95 million to $100 million.
Because Nkarta is pre-revenue and unprofitable, its price is driven less by near-term earnings and more by clinical data, regulatory milestones, financing, and investor sentiment. A move toward the target would almost certainly depend on positive trial results for NKX019 and renewed confidence that the pipeline can create meaningful value, rather than on fundamental earnings growth in the near term.
What Could Support a Move Toward the Target
The core supporting factor is the autoimmune pipeline. Analysts have pointed to progress in Nkarta's NKX019 program, including a reported regulatory update on the lead autoimmune program and clinical data presentations. The company has highlighted a cash position of roughly $243 million and a runway extending into 2029, which reduces near-term dilution risk relative to earlier-stage peers. Off-the-shelf (allogeneic) NK cell therapies remain an area of scientific and investor interest, and a data-driven inflection could re-rate the shares meaningfully.
What Could Prevent the Target From Being Reached
The principal risks are substantial. Nkarta is clinical-stage, meaning its valuation hinges on trial outcomes that are inherently uncertain. Continued cash burn, the possibility of future equity raises that dilute shareholders, and execution risk in manufacturing and regulatory pathways all weigh on the stock. The share price has fallen dramatically, and the shares trade below both their 50-day and 200-day moving averages. Even the most cautious current analyst target is far above the market price, which underscores how much the market is currently discounting the pipeline.
Technical Levels and Market Structure
NKTX has traded within a 52-week range of roughly $1.13 to $3.72, and the stock has recently broken below prior consolidation zones. The 50-day moving average sits near $2.32 and the 200-day moving average near $2.52, meaning the price is trading well beneath both, a sign of sustained downward momentum. The $1.13 area represents the recent low and a key support level to watch, while the $3.72 prior high is the most relevant longer-term resistance zone on the way toward any higher objective.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though the exact window varies by firm. Investors should monitor upcoming NKX019 clinical data readouts, regulatory updates on the autoimmune program, quarterly cash-burn figures, any financing announcements, and analyst target revisions. Because the stock is so far below even the lowest target, changes in sentiment and clinical news are likely to matter more than routine earnings in determining the near-term path. From what I see, this is important because momentum shifts can happen quickly on news.
Using AI Daily Buy/Sell Signals in Research
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, keep an eye on existing positions, and identify changing trends more efficiently than manual screening alone. For a volatile, news-driven name like NKTX, a systematic, data-based signal stream can help filter noise and highlight actionable changes in momentum. I’m watching this closely as part of my process.
Final Assessment
The $11 central target is an average of analyst expectations, not a guarantee, and it sits far above the current price near $1.35, requiring a very large move of roughly 700%. The bull case rests on Nkarta's NKX019 autoimmune pipeline and a reported cash runway into 2029, while the bear case centers on clinical-stage risk, cash burn, dilution, and a share price that has fallen well below its moving averages. Analysts remain broadly bullish on ratings but have been trimming targets, reflecting recalibrated expectations rather than abandoned conviction. Whether NKTX can reach $11 ultimately depends on clinical execution and data, and investors should watch upcoming trial readouts and financing developments closely. One thing that stands out is how clinical milestones could shift the entire setup.
Exploring Tickeron AI Tools for Deeper Analysis
In my view, incorporating AI-driven resources has become a practical part of reviewing complex names like this one. Tickeron’s suite of tools, including the AI Daily Buy/Sell Signals, helps surface patterns and signals across a broad universe of stocks without replacing individual judgment. I find it useful for cross-checking technical setups and momentum shifts alongside traditional research, especially when evaluating clinical-stage biotechs where data events can move prices quickly. This approach keeps the workflow efficient while staying grounded in observable market behavior.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
NKTX sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for NKTX moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NKTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for NKTX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 66 cases where NKTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for NKTX just turned positive on November 04, 2026. Looking at past instances where NKTX's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +13.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTX advanced for three days, in 208 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.500) is normal, around the industry mean (3.498). P/E Ratio (-1.088) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer
Industry Biotechnology
Advertisement